NeuroStar TMS Therapy® — Help Your Patients Reach Remission and Stay There

NeuroStar is the only TMS treatment with demonstrated durability in depression over 1 year20


Read more about the proven short- and long-term efficacy of NeuroStar TMS Therapy for patients with major depressive disorder:

Significant response was maintained 12 months after acute depression treatment20

In a naturalistic clinical study in 257 patients who did not benefit from antidepressant medications, NeuroStar TMS Therapy offered durable effect over 1 year following acute treatment:

  • 67.7% of patients responded to treatment
  • 45.1% reached remission

36.2% of patients received NeuroStar TMS Therapy reintroduction (average of 16 treatments). Long-term durability of effect has not been established in a randomized trial. Trial design used physician-directed standard of care.

In acute phase of treatment, 1 in 2 patients responded to therapy and 1 in 3 reached remission6

  • Consistent response and remission rates across a broad range of antidepressant treatment resistance6
    • Patients with both low and high treatment-resistant depression who are treated with NeuroStar TMS Therapy experience significant benefits after 4 to 6 weeks of treatment.

CGI-S outcomes in acute phase of treatment

NeuroStar end of acute treatment outcomes

An open-label, multicenter study included 307 (acute phase) evaluable, unipolar, non-psychotic MDD patients in post-market use who were evaluated after treatment with NeuroStar TMS Therapy.6

View NeuroStar TMS Therapy safety data

Clinical results demonstrated an improvement in depression symptoms

  • In an NIMH-funded, independent, randomized, controlled trial, patients treated with TMS using the NeuroStar TMS System were four times more likely to achieve remission compared to patients receiving sham treatment (P=0.0173; odds ratio=4.05)8
  • Significant improvement from baseline with NeuroStar TMS Therapy was observed as early as 2 weeks after treatment and at 4 and 6 weeks (P=0.0006)5

NeuroStar TMS Therapy is backed by the largest clinical data set of any TMS system

  • Two multisite, randomized, controlled trials demonstrated the clinically significant antidepressant effect of NeuroStar TMS Therapy7,8
  • Two open-label extension studies replicated results of clinical studies5,9
  • One prospective, naturalistic study confirmed results in real-world practice6
  • Two open-label, long-term, follow-up studies10,19

Ongoing Clinical Trials

Neuronetics continues to support clinical trial programs. The following are sponsored by Neuronetics:

  • Adolescent Depression Study – The focus of this study is understanding the response to TMS therapy in adolescents suffering from Major Depressive Disorder (MDD). Participants in this study are antidepressant medication free. This study is currently enrolling patients who are
    • Male or Female 12-21;
    • Diagnosis of Major Depressive Disorder;
    • Duration of current episode of depression ≥ 4 weeks and < 3 years.
  • Study locations include:
    • Gainesville, FL
    • Pensacola, FL
    • Louisville, KY
    • Baltimore, MD
    • Rochester, MN
    • Lebanon, NH
    • Columbus, OH
    • Cincinnati, OH
    • East Providence, RI
    • Charleston, SC
    • Salt Lake City, UT
    • Calgary, Alberta

    Please visit for more information on this study.

Other studies using NeuroStar/Neuronetics devices

If you are interested in conducting an Investigator Initiated Trial, please contact Neuronetics Customer Service at
1-877-600-7555 (option 3).